Caliway Biopharmaceuticals, a Taiwan-based biopharmaceutical company, announced on Monday that it has completed enrolment of subjects in the CBL-0201EFP Phase 2-stage 2 study.

The study, an open-label trial, is intended to assess the efficacy, safety, and tolerability of CBL-0201EFP in treating subjects with moderate to severe cellulite.

A total of 23 subjects were enrolled in the study and all are to receive the CBL-514 treatment. The efficacy and safety of the trial is to be assessed at follow-up visits at week four and week 13 after the last treatment. The study's topline outcome is expected to be revealed in the second quarter of 2024.

The company says that the product is a first-in-class small-molecule drug and is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis to decrease subcutaneous adiposity in treatment areas in animal studies without causing any systematic side impacts on the central nervous system, cardiovascular system and respiratory system.